Immunotherapy can delay Type 1
A landmark trial shows that an immunotherapy drug can delay Type 1 diabetes by an average of three years. Previously, in 2019, researchers from the
A landmark trial shows that an immunotherapy drug can delay Type 1 diabetes by an average of three years. Previously, in 2019, researchers from the
JDRF Impact Report 2020-21 JDRF has published its latest annual report highlighting the charities achievements. The Impact Report 2019-2020 explains how the Type 1 diabetes
Research has shown that losing just two to three kilograms (KGs) of weight and exercising for two years almost halves the risk of developing Type
Join JDRF on Thursday 11 February for a spectacular online event to mark 100 years since the discovery of insulin and raise money for the
Alopecia UK has joined the Connect Immune Research initiative, alongside founding members JDRF, MS Society, Versus Arthritis, and supporting partner the British Society for Immunology.
Welcome to the Academy! A new Diabetes Technology Network (DTN) education programme, initially for HCPs, has launched. Simply called Academy, it is bringing info on
A UK diabetes professor has been presented with Belgium’s highest scientific award for his discoveries that have changed the understanding, diagnosis, and treatment of genetic
A team of physicians from Baylor College of Medicine, Texas Children’s Hospital and the University of California, San Francisco, have announced the first case of a patient with
Flash glucose monitors help youths with Type 1 diabetes better monitor their blood sugar levels, but it doesn’t improve glucose control, a study from the
An investigational once-daily pill added to optimised insulin therapy has been shown to reduce HbA1c among adults with Type 1 diabetes during a 12-week trial